{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:12:45Z","timestamp":1783440765669,"version":"3.54.6"},"reference-count":123,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:00:00Z","timestamp":1760745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Burkitt lymphoma (BL) is a rare, aggressive B-cell lymphoma that is characterized by rapid tumor proliferation and frequent extra-nodal involvement. While prompt diagnosis and initiation of highly intensive chemotherapy results in cure rates over 90% in children and adolescents, outcomes in adults are more modest, as comorbidities and advancing age may compromise treatment tolerability. In recent years, intermediate-intensity regimens have been developed for BL. These are highly effective in patients of all ages and associated with significantly less treatment-related toxicity compared to traditional high-dose chemotherapy. This was demonstrated in a recent randomized study of dose-intensive R-CODOX-M\/R-IVAC compared to the reduced-intensity DA-EPOCH-R regimen, which was associated with equivalent outcomes but with significantly fewer side effects. Regardless of the chemotherapy platform, CNS involvement at baseline predicts a significantly inferior outcome, and the development of an optimal approach for these patients is an area of unmet need in BL therapeutics. Patients with relapsed or refractory disease following frontline therapy have very short survival times, as currently available salvage options are largely ineffective. In this regard, novel agents such as anti-CD19 CAR-T cells and bi-specific antibodies are under development in BL. It is hoped that progress in novel drug development, alongside improved understanding of BL biology, to further elucidate its genetic and epigenetic vulnerabilities, will lead to improved outcomes for patients in the future.<\/jats:p>","DOI":"10.3390\/cancers17203372","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:44:10Z","timestamp":1760957050000},"page":"3372","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel Molecular Insights and Evolution of Less Toxic Therapeutic Strategies in Burkitt Lymphoma"],"prefix":"10.3390","volume":"17","author":[{"given":"Coen J.","family":"Lap","sequence":"first","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC 20007, USA"},{"name":"Department of Hematology and Oncology, Georgetown University Hospital, Washington, DC 20007, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieron","family":"Dunleavy","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC 20007, USA"},{"name":"Department of Hematology and Oncology, Georgetown University Hospital, Washington, DC 20007, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/bjs.18004619704","article-title":"A Sarcoma Involving the Jaws in African Children","volume":"46","author":"Burkitt","year":"1958","journal-title":"J. Br. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41408-024-01138-z","article-title":"Global, Regional, and National Burden of Burkitt Lymphoma from 1990 to 2021 and Predictions to 2030: A Systematic Analysis for the Global Burden of Disease Study 2021","volume":"14","author":"Wang","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S1470-2045(08)70175-X","article-title":"Part I: Cancer in Indigenous Africans\u2014Burden, Distribution, and Trends","volume":"9","author":"Parkin","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/ijc.34618","article-title":"Incidence of Burkitt Lymphoma in the United States during 2000 to 2019","volume":"153","author":"Mburu","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7824","DOI":"10.1073\/pnas.79.24.7824","article-title":"Human C-Myc Onc Gene Is Located on the Region of Chromosome 8 That Is Translocated in Burkitt Lymphoma Cells","volume":"79","author":"Bregni","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.1073\/pnas.79.24.7837","article-title":"Translocation of the C-Myc Gene into the Immunoglobulin Heavy Chain Locus in Human Burkitt Lymphoma and Murine Plasmacytoma Cells","volume":"79","author":"Taub","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The Genetic Landscape of Mutations in Burkitt Lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1182\/blood.2019001880","article-title":"The Whole-Genome Landscape of Burkitt Lymphoma Subtypes","volume":"134","author":"Panea","year":"2019","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ajh.22189","article-title":"Intensive Short-term Chemotherapy Regimen Induces High Remission Rate (over 90%) and Event-free Survival Both in Children and Adult Patients with Advanced Sporadic Burkitt Lymphoma\/Leukemia","volume":"87","author":"Todeschini","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-Intensity Therapy in Adults with Burkitt\u2019s Lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e966","DOI":"10.1016\/S2352-3026(23)00279-X","article-title":"R-CODOX-M\/R-IVAC versus DA-EPOCH-R in Patients with Newly Diagnosed Burkitt Lymphoma (HOVON\/SAKK): Final Results of a Multicentre, Phase 3, Open-Label, Randomised Trial","volume":"10","author":"Chamuleau","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.20.00303","article-title":"Multicenter Study of Risk-Adapted Therapy with Dose-Adjusted EPOCH-R in Adults with Untreated Burkitt Lymphoma","volume":"38","author":"Roschewski","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.3324\/haematol.2020.270876","article-title":"Outcomes of Burkitt Lymphoma with Central Nervous System Involvement: Evidence from a Large Multicenter Cohort Study","volume":"106","author":"Zayac","year":"2021","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1056\/NEJMc2501018","article-title":"Glofitamab with Polatuzumab Vedotin in Refractory Burkitt\u2019s Lymphoma","volume":"392","author":"Prica","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1200\/JCO.24.00070","article-title":"Lymphoma Classifications, How to Develop a Future Unified Taxonomy","volume":"42","author":"Campo","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMra2025746","article-title":"Burkitt\u2019s Lymphoma","volume":"387","author":"Roschewski","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/apm.13018","article-title":"Endemic Burkitt Lymphoma\u2014An Aggressive Childhood Cancer Linked to Plasmodium falciparum Exposure, but Not to Exposure to Other Malaria Parasites","volume":"128","author":"Quintana","year":"2020","journal-title":"APMIS"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood-2018-04-844472","article-title":"How I Treat Burkitt Lymphoma in Children, Adolescents, and Young Adults in Sub-Saharan Africa","volume":"132","author":"Gopal","year":"2018","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e27275","DOI":"10.1002\/pbc.27275","article-title":"The Changing Clinical Pattern of Endemic Burkitt Lymphoma in Western Africa: Experience from a Tertiary Center in Ghana","volume":"65","author":"Offor","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"102513","DOI":"10.1016\/j.canep.2023.102513","article-title":"Lymphoid Blood Cancers, Incidence and Survival 2005-2023: A Report from the UK\u2019s Haematological Malignancy Research Network","volume":"88","author":"Lamb","year":"2024","journal-title":"Cancer Epidemiol."},{"key":"ref_23","first-page":"443","article-title":"2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA. Cancer J. Clin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2018-04-842559","article-title":"Immunodeficiency-Associated Lymphoproliferative Disorders: Time for Reappraisal?","volume":"132","author":"Natkunam","year":"2018","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1182\/bloodadvances.2021004458","article-title":"HIV-Associated Burkitt Lymphoma: Outcomes from a US-UK Collaborative Analysis","volume":"5","author":"Alderuccio","year":"2021","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jnci\/djt158","article-title":"Temporal Trends in Presentation and Survival for HIV-Associated Lymphoma in the Antiretroviral Therapy Era","volume":"105","author":"Gopal","year":"2013","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1182\/blood-2010-03-275917","article-title":"AIDS-Related Burkitt Lymphoma in the United States: What Do Age and CD4 Lymphocyte Patterns Tell Us about Etiology and\/or Biology?","volume":"116","author":"Simard","year":"2010","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2011-08-373738","article-title":"How I Treat HIV-Associated Lymphoma","volume":"119","author":"Dunleavy","year":"2012","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1200\/JCO.20.03288","article-title":"Burkitt Lymphoma International Prognostic Index","volume":"39","author":"Olszewski","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00428-022-03404-6","article-title":"Diagnostic Approaches and Future Directions in Burkitt Lymphoma and High-Grade B-Cell Lymphoma","volume":"482","author":"King","year":"2023","journal-title":"Virchows Arch."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.MP.0000019577.73786.64","article-title":"The Distinction between Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma with c-Myc Rearrangement","volume":"15","author":"Nakamura","year":"2002","journal-title":"Mod. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1016\/S2352-3026(24)00351-X","article-title":"Diagnosis and Treatment of Burkitt Lymphoma in Adults: Clinical Practice Guidelines from ERN-EuroBloodNet","volume":"12","author":"Ribrag","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1634\/theoncologist.11-4-375","article-title":"Burkitt\u2019s Lymphoma: Clinicopathologic Features and Differential Diagnosis","volume":"11","author":"Ferry","year":"2006","journal-title":"Oncologist"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.humpath.2023.07.008","article-title":"Clinicopathologic and Genetic Features of the Starry-Sky Pattern in Double-Expressor Diffuse Large B-Cell Lymphoma","volume":"139","author":"Sung","year":"2023","journal-title":"Hum. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1309\/AJCP93LJPTRQPDKR","article-title":"Immunophenotypic Variations of Burkitt Lymphoma","volume":"134","author":"Kelemen","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/PAS.0000000000000804","article-title":"Prognostic Impact of MUM1\/IRF4 Expression in Burkitt Lymphoma (BL): A Reappraisal of 88 BL Patients in Japan","volume":"41","author":"Satou","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/jcp.2007.047977","article-title":"Epstein\u2013Barr Virus and Burkitt Lymphoma","volume":"84","author":"Brady","year":"2008","journal-title":"Postgrad. Med. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-9378-9-34","article-title":"The Role of EBV in the Pathogenesis of Burkitt\u2019s Lymphoma: An Italian Hospital Based Survey","volume":"9","author":"Pannone","year":"2014","journal-title":"Infect. Agent. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1038\/s41388-023-02846-9","article-title":"MYC Directly Transactivates CR2\/CD21, the Receptor of the Epstein\u2013Barr Virus, Enhancing the Viral Infection of Burkitt Lymphoma Cells","volume":"42","author":"Molina","year":"2023","journal-title":"Oncogene"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus Particles in Cultured Lymphoblasts from Burkitt\u2019s Lymphoma","volume":"283","author":"Epstein","year":"1964","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.21037\/aol-21-18","article-title":"Reframing Burkitt Lymphoma: Virology Not Epidemiology Defines Clinical Variants","volume":"5","author":"Rochford","year":"2021","journal-title":"Ann. Lymphoma"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ijc.2910290406","article-title":"Final Case Reporting from the Ugandan Prospective Study of the Relationship between Ebv and Burktit\u2019s Lymphoma","volume":"29","author":"Geser","year":"1982","journal-title":"Int. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nri1201","article-title":"B Cells under Influence: Transformation of B Cells by Epstein\u2013Barr Virus","volume":"3","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ijc.10372","article-title":"Promiscuous Expression of Epstein-Barr Virus Genes in Burkitt\u2019s Lymphoma from the Central African Country Malawi","volume":"99","author":"Xue","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Fitzsimmons, L., and Kelly, G. (2017). EBV and Apoptosis: The Viral Master Regulator of Cell Fate?. Viruses, 9.","DOI":"10.3390\/v9110339"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/emboj\/21.5.954","article-title":"Epstein-Barr Virus RNA Confers Resistance to Interferon-Alpha-Induced Apoptosis in Burkitt\u2019s Lymphoma","volume":"21","author":"Nanbo","year":"2002","journal-title":"EMBO J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.virol.2010.10.029","article-title":"Epstein\u2013Barr Virus Nuclear Antigen 1 (EBNA1) Confers Resistance to Apoptosis in EBV-Positive B-Lymphoma Cells through up-Regulation of Survivin","volume":"410","author":"Lu","year":"2011","journal-title":"Virology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1631\/jzus.B1200189","article-title":"Epstein-Barr Virus Interactions with the Bcl-2 Protein Family and Apoptosis in Human Tumor Cells","volume":"14","author":"Fu","year":"2013","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1182\/blood-2018-09-871418","article-title":"Genome-Wide Discovery of Somatic Coding and Noncoding Mutations in Pediatric Endemic and Sporadic Burkitt Lymphoma","volume":"133","author":"Grande","year":"2019","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0092-8674(00)00078-7","article-title":"Class Switch Recombination and Hypermutation Require Activation-Induced Cytidine Deaminase (AID), a Potential RNA Editing Enzyme","volume":"102","author":"Muramatsu","year":"2000","journal-title":"Cell"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ruiz, J.F., G\u00f3mez-Gonz\u00e1lez, B., and Aguilera, A. (2011). AID Induces Double-Strand Breaks at Immunoglobulin Switch Regions and c-MYC Causing Chromosomal Translocations in Yeast THO Mutants. PLoS Genet., 7.","DOI":"10.1371\/journal.pgen.1002009"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.molcel.2009.11.007","article-title":"AID Produces DNA Double-Strand Breaks in Non-Ig Genes and Mature B Cell Lymphomas with Reciprocal Chromosome Translocations","volume":"36","author":"Robbiani","year":"2009","journal-title":"Mol. Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.cell.2008.09.062","article-title":"AID Is Required for the Chromosomal Breaks in C-Myc That Lead to c-Myc\/IgH Translocations","volume":"135","author":"Robbiani","year":"2008","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cell.2015.07.019","article-title":"Plasmodium Infection Promotes Genomic Instability and AID-Dependent B Cell Lymphoma","volume":"162","author":"Robbiani","year":"2015","journal-title":"Cell"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Thorley-Lawson, D., Deitsch, K.W., Duca, K.A., and Torgbor, C. (2016). The Link between Plasmodium Falciparum Malaria and Endemic Burkitt\u2019s Lymphoma\u2014New Insight into a 50-Year-Old Enigma. PLOS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005331"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2017-11-742577","article-title":"The MYC Oncogene Is a Global Regulator of the Immune Response","volume":"131","author":"Casey","year":"2018","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC Oncogene \u2014the Grand Orchestrator of Cancer Growth and Immune Evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_59","unstructured":"(1990). The Pathogenesis of Burkitt\u2019s Lymphoma. Advances in Cancer Research, Elsevier."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ijc.2910170108","article-title":"Characteristic Chromosomal Abnormalities in Biopsies and Lymphoid-cell Lines from Patients with Burkitt and Non-burkitt Lymphomas","volume":"17","author":"Zech","year":"1976","journal-title":"Int. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"38591","DOI":"10.18632\/oncotarget.5774","article-title":"MYC -Driven Aggressive B-Cell Lymphomas: Biology, Entity, Differential Diagnosis and Clinical Management","volume":"6","author":"Cai","year":"2015","journal-title":"Oncotarget"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1182\/blood-2013-05-498329","article-title":"Understanding MYC-Driven Aggressive B-Cell Lymphomas: Pathogenesis and Classification","volume":"122","author":"Ott","year":"2013","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/hmg\/1.8.625","article-title":"Variable Breakpoints in Burkitt Lymphoma Cells with Chromosomal t(8; 14) Translocation Separate c-Myc and the IgH Locus up to Several Hundred Kb","volume":"1","author":"Joos","year":"1992","journal-title":"Hum. Mol. Genet."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1073\/pnas.83.9.2984","article-title":"Chromosomal Breakpoints and Structural Alterations of the C-Myc Locus Differ in Endemic and Sporadic Forms of Burkitt Lymphoma","volume":"83","author":"Pelicci","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_65","first-page":"457","article-title":"MYC Deregulation in Lymphoid Tumors: Molecular Mechanisms, Clinical Consequences and Therapeutic Implications","volume":"1846","author":"Sewastianik","year":"2014","journal-title":"Biochim. Biophys. Acta BBA-Rev. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1182\/bloodadvances.2023009731","article-title":"High-Grade B-Cell Lymphoma, Not Otherwise Specified: A Multi-Institutional Retrospective Study","volume":"7","author":"Zayac","year":"2023","journal-title":"Blood Adv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood.2024024048","article-title":"Testing for t(3;8) in MYC\/BCL6-Rearranged Large B-Cell Lymphoma Identifies a High-Risk Subgroup with Inferior Survival","volume":"144","author":"Maybury","year":"2024","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/bloodadvances.2018023572","article-title":"High-Resolution Architecture and Partner Genes of MYC Rearrangements in Lymphoma with DLBCL Morphology","volume":"2","author":"Chong","year":"2018","journal-title":"Blood Adv."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.2024024251","article-title":"Motive and Opportunity: MYC Rearrangements in High-Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements (an LLMPP Study)","volume":"144","author":"Hilton","year":"2024","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa055351","article-title":"A Biologic Definition of Burkitt\u2019s Lymphoma from Transcriptional and Genomic Profiling","volume":"354","author":"Hummel","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_71","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours, International Agency for Research on Cancer. [Revised 4th ed.]."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1084\/jem.167.2.353","article-title":"The E Mu-Myc Transgenic Mouse. A Model for High-Incidence Spontaneous Lymphoma and Leukemia of Early B Cells","volume":"167","author":"Harris","year":"1988","journal-title":"J. Exp. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood.2022016534","article-title":"Genetic Subgroups Inform on Pathobiology in Adult and Pediatric Burkitt Lymphoma","volume":"141","author":"Thomas","year":"2023","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood.2021012081","article-title":"SHMT2 Inhibition Disrupts the TCF3 Transcriptional Survival Program in Burkitt Lymphoma","volume":"139","author":"Wilke","year":"2022","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt Lymphoma Pathogenesis and Therapeutic Targets from Structural and Functional Genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"a014407","DOI":"10.1101\/cshperspect.a014407","article-title":"MYC and the Control of Apoptosis","volume":"4","author":"McMahon","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1128\/JVI.72.11.9150-9156.1998","article-title":"Epstein-Barr Virus Contributes to the Malignant Phenotype and to Apoptosis Resistance in Burkitt\u2019s Lymphoma Cell Line Akata","volume":"72","author":"Komano","year":"1998","journal-title":"J. Virol."},{"key":"ref_78","first-page":"2775","article-title":"TP3 Binding Domain Mutations Are Bad News in Burkitt Lymphoma","volume":"109","author":"Cairo","year":"2024","journal-title":"Haematologica"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/sj.leu.2403254","article-title":"Inactivation of the ARF\u2013MDM-2\u2013P53 Pathway in Sporadic Burkitt\u2019s Lymphoma in Children","volume":"18","author":"Wilda","year":"2004","journal-title":"Leukemia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41388-021-02069-w","article-title":"The Emerging Roles of G\u03b112\/13 Proteins on the Hallmarks of Cancer in Solid Tumors","volume":"41","author":"Rasheed","year":"2022","journal-title":"Oncogene"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood-2015-07-659938","article-title":"GNA13 Loss in Germinal Center B Cells Leads to Impaired Apoptosis and Promotes Lymphoma in Vivo","volume":"127","author":"Healy","year":"2016","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature13765","article-title":"Loss of Signalling via G\u03b113 in Germinal Centre B-Cell-Derived Lymphoma","volume":"516","author":"Muppidi","year":"2014","journal-title":"Nature"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2024.02.011","article-title":"SMARCA4 Is a Haploinsufficient B Cell Lymphoma Tumor Suppressor That Fine-Tunes Centrocyte Cell Fate Decisions","volume":"42","author":"Deng","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1182\/blood-2012-06-437624","article-title":"Targeted Genomic Sequencing of Pediatric Burkitt Lymphoma Identifies Recurrent Alterations in Antiapoptotic and Chromatin-Remodeling Genes","volume":"120","author":"Wang","year":"2012","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1158\/2643-3230.BCD-24-0240","article-title":"DNA Methylation Epitypes of Burkitt Lymphoma with Distinct Molecular and Clinical Features","volume":"6","author":"Thomas","year":"2025","journal-title":"Blood Cancer Discov."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdh262","article-title":"Treatment of Burkitt\u2019s\/Burkitt-like Lymphoma in Adolescents and Adults: A 20-Year Experience from the Norwegian Radium Hospital with the Use of Three Successive Regimens","volume":"15","author":"Smeland","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1182\/blood.2019004099","article-title":"The Treatment of Burkitt Lymphoma in Adults","volume":"137","author":"Crombie","year":"2021","journal-title":"Blood"},{"key":"ref_88","first-page":"5810","article-title":"The Chemotherapy of Lymphomas: Looking Back, Moving Forward--the Richard and Hinda Rosenthal Foundation Award Lecture","volume":"47","author":"Hubbard","year":"1987","journal-title":"Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1200\/JCO.1991.9.6.941","article-title":"Effective Treatment of Small-Noncleaved-Cell Lymphoma with High-Intensity, Brief-Duration Chemotherapy","volume":"9","author":"McMaster","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and Children with Small Non-Cleaved-Cell Lymphoma Have a Similar Excellent Outcome When Treated with the Same Chemotherapy Regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An International Evaluation of CODOX-M and CODOX-M Alternating with IVAC in Adult Burkitt\u2019s Lymphoma: Results of United Kingdom Lymphoma Group LY06 Study","volume":"13","author":"Mead","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A Prospective Clinicopathologic Study of Dose-Modified CODOX-M\/IVAC in Patients with Sporadic Burkitt Lymphoma Defined Using Cytogenetic and Immunophenotypic Criteria (MRC\/NCRI LY10 Trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1042819031000141301","article-title":"Modified Magrath Regimens for Adults with Burkitt and Burkitt-Like Lymphomas: Preserved Efficacy with Decreased Toxicity","volume":"45","author":"Lacasce","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/annonc\/mdq677","article-title":"Evaluation of the Addition of Rituximab to CODOX-M\/IVAC for Burkitt\u2019s Lymphoma: A Retrospective Analysis","volume":"22","author":"Barnes","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1093\/annonc\/mdt414","article-title":"A Multicenter Phase II Study Incorporating High-Dose Rituximab and Liposomal Doxorubicin into the CODOX-M\/IVAC Regimen for Untreated Burkitt\u2019s Lymphoma","volume":"24","author":"Evens","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","article-title":"AMC 048: Modified CODOX-M\/IVAC-Rituximab Is Safe and Effective for HIV-Associated Burkitt Lymphoma","volume":"126","author":"Noy","year":"2015","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/annonc\/mdi403","article-title":"Burkitt Lymphoma in Adults: A Prospective Study of 72 Patients Treated with an Adapted Pediatric LMB Protocol","volume":"16","author":"Casassus","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","article-title":"Hyper-CVAD Program in Burkitt\u2019s-Type Adult Acute Lymphoblastic Leukemia","volume":"17","author":"Thomas","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus Rituximab for the Treatment of Adult Burkitt and Burkitt-type Lymphoma or Acute Lymphoblastic Leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved Outcome of Adult Burkitt Lymphoma\/Leukemia with Rituximab and Chemotherapy: Report of a Large Prospective Multicenter Trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.20143","article-title":"Intensive Chemotherapy with and without Cranial Radiation for Burkitt Leukemia and Lymphoma: Final Results of Cancer and Leukemia Group B Study 9251","volume":"100","author":"Rizzieri","year":"2004","journal-title":"Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.12736","article-title":"Improved Efficacy Using Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Aggressive Lymphomas: Cancer and Leukemia Group B Study 10 002","volume":"165","author":"Rizzieri","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/S0140-6736(15)01317-3","article-title":"Rituximab and Dose-Dense Chemotherapy for Adults with Burkitt\u2019s Lymphoma: A Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"387","author":"Ribrag","year":"2016","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3324\/haematol.2023.283342","article-title":"Feasibility and Outcomes after Dose Reduction of Immunochemotherapy in Young Adults with Burkitt Lymphoma and Leukemia: Results of the BURKIMAB14 Trial","volume":"109","author":"Ribera","year":"2023","journal-title":"Haematologica"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","article-title":"The Role of Tumor Histogenesis, FDG-PET, and Short-Course EPOCH with Dose-Dense Rituximab (SC-EPOCH-RR) in HIV-Associated Diffuse Large B-Cell Lymphoma","volume":"115","author":"Dunleavy","year":"2010","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-Adjusted EPOCH-R (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin, and Rituximab) in Untreated Aggressive Diffuse Large B-Cell Lymphoma with MYC Rearrangement: A Prospective, Multicentre, Single-Arm Phase 2 Study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.1983.1.11.677","article-title":"Central Nervous System Involvement in American Burkitt\u2019s Lymphoma","volume":"1","author":"Sariban","year":"1983","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdl327","article-title":"Incidence and Risk Factors of Central Nervous System Recurrence in Aggressive Lymphoma\u2014A Survey of 1693 Patients Treated in Protocols of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL)","volume":"18","author":"Boehme","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3324\/haematol.2020.278181","article-title":"Be Mindful of the Central Nervous System in Burkitt Lymphoma","volume":"106","author":"Roschewski","year":"2021","journal-title":"Haematologica"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a Randomized International Study of High-Risk Central Nervous System B Non-Hodgkin Lymphoma and B Acute Lymphoblastic Leukemia in Children and Adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood.2020005329","article-title":"Tackling Burkitt When It\u2019s Back","volume":"135","author":"Simkins","year":"2020","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"358","DOI":"10.4143\/crt.2013.047","article-title":"Clinical Outcome of Relapsed or Refractory Burkitt Lymphoma and Mature B-Cell Lymphoblastic Leukemia in Children and Adolescents","volume":"46","author":"Kim","year":"2014","journal-title":"Cancer Res. Treat."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.1002\/ajh.24720","article-title":"Outcomes of Adults with Relapsed or Refractory Burkitt and High-Grade B-Cell Leukemia\/Lymphoma","volume":"92","author":"Short","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bbmt.2012.11.016","article-title":"Autologous and Allogeneic Transplantation for Burkitt Lymphoma Outcomes and Changes in Utilization: A Report from the Center for International Blood and Marrow Transplant Research","volume":"19","author":"Maramattom","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.1996.14.9.2465","article-title":"Adult Burkitt\u2019s and Burkitt-like Non-Hodgkin\u2019s Lymphoma--Outcome for Patients Treated with High-Dose Therapy and Autologous Stem-Cell Transplantation in First Remission or at Relapse: Results from the European Group for Blood and Marrow Transplantation","volume":"14","author":"Sweetenham","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41409-018-0235-0","article-title":"CAR T Cells Induce a Complete Response in Refractory Burkitt Lymphoma","volume":"53","author":"Avigdor","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1080\/10428194.2022.2076853","article-title":"Durable Remissions in Two Adult Patients with Burkitt Lymphoma Following Anti-CD19 CAR T-Cell Therapy: A Single Center Experience","volume":"63","author":"Seitter","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_118","first-page":"103477","article-title":"CAR T-Cell Therapy Combined with Autologous Hematopoietic Cell Transplantation in Patients with Refractory\/Relapsed Burkitt Lymphoma","volume":"73","author":"Liu","year":"2025","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1182\/blood.2024026831","article-title":"Outcomes among Adult Recipients of CAR T-Cell Therapy for Burkitt Lymphoma","volume":"145","author":"Samples","year":"2025","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1080\/10428194.2024.2447882","article-title":"Salvage Therapy for Burkitt Lymphoma with Glofitamab: A Case Report","volume":"66","author":"Almeida","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1017\/pcm.2023.1","article-title":"Clinical Application of Circulating Cell-Free Lymphoma DNA for Fast and Precise Diagnosis of Burkitt Lymphoma: Precision Medicine for Sub-Saharan Africa","volume":"1","author":"Chamba","year":"2023","journal-title":"Camb. Prisms Precis. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1111\/bjh.19425","article-title":"Targeted Therapy in Burkitt Lymphoma: Small Molecule Inhibitors under Investigation","volume":"204","author":"Habermann","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"21820","DOI":"10.18632\/oncotarget.25072","article-title":"Pre-Clinical Activity of Targeting the PI3K\/Akt\/mTOR Pathway in Burkitt Lymphoma","volume":"9","author":"Bhatti","year":"2018","journal-title":"Oncotarget"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/20\/3372\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:00:46Z","timestamp":1760958046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/20\/3372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,18]]},"references-count":123,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["cancers17203372"],"URL":"https:\/\/doi.org\/10.3390\/cancers17203372","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,18]]}}}